← The Wire
REGNNasdaq
REGENERON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · NY · CIK 872589
Regeneron Pharmaceuticals discovers, develops, and commercializes medicines for serious diseases
⚡ Elevated coverage
$64.18B
Market cap
$631.81
Last close
-0.2%
1D
+3.1%
5D
734K
Volume
Price · last 39 sessions-10.9%
May 4L $600.66 · H $723.41Jun 29
165
Total filings
Jun 17, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 17, 202610-Q10-QApr 29, 20268-KResults of OperationsApr 29, 2026DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSApr 24, 2026DEF 14ADEFINITIVE PROXY STATEMENTApr 24, 20268-KResults of OperationsApr 8, 202610-K10-KFeb 4, 20268-KResults of OperationsJan 30, 20268-KResults of Operations · Reg FD DisclosureJan 12, 202610-Q10-QOct 28, 20258-KResults of OperationsOct 28, 20258-KResults of OperationsOct 6, 202510-Q10-QAug 1, 20258-KResults of OperationsAug 1, 20258-KShareholder VoteJun 18, 202510-Q10-QApr 29, 20258-KResults of OperationsApr 29, 2025DEFA14ADEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALSApr 29, 2025DEF 14ADEFINITIVE PROXY STATEMENTApr 29, 202510-K10-KFeb 5, 20258-KResults of Operations · Company UpdateFeb 4, 20258-KResults of Operations · Reg FD DisclosureJan 13, 202510-Q10-QOct 31, 20248-KResults of OperationsOct 31, 20248-KResults of OperationsOct 7, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KResults of OperationsJul 8, 20248-KShareholder VoteJun 20, 202410-Q10-QMay 2, 20248-KResults of OperationsMay 2, 2024DEFA14AREGENERON PHARMACEUTICALS, INC. - DEFA14AApr 25, 2024DEF 14AREGENERON PHARMACEUTICALS, INC. - DEF 14AApr 25, 202410-K10-KFeb 5, 20248-KResults of OperationsFeb 2, 20248-KExecutive ChangeJan 31, 20248-KResults of Operations · Reg FD DisclosureJan 8, 202410-Q10-QNov 2, 20238-KResults of OperationsNov 2, 20238-KResults of OperationsOct 5, 20238-K/AShareholder VoteSep 8, 20238-KExecutive ChangeSep 8, 2023SC 13DSC 13DAug 18, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KBylaw Amendment · Shareholder VoteJun 14, 2023DEFA14ADEFA14AMay 17, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEFA14AREGENERON PHARMACEUTICALS, INC. - DEFA14AApr 21, 2023DEF 14AREGENERON PHARMACEUTICALS, INC. - DEF 14AApr 21, 20238-KExecutive ChangeApr 17, 20238-KResults of OperationsApr 10, 20238-KMaterial Agreement · New Debt / ObligationMar 29, 202310-K10-KFeb 6, 20238-KResults of OperationsFeb 3, 2023SC 13GFILING REGENERON PHARMACEUTICALS, INC.Jan 11, 20238-KResults of Operations · Reg FD DisclosureJan 9, 20238-KMaterial Agreement · Agreement TerminatedDec 20, 202210-Q10-QNov 3, 20228-KResults of OperationsNov 3, 20228-KExecutive ChangeOct 3, 202210-Q10-QAug 3, 20228-KResults of OperationsAug 3, 20228-KShareholder VoteJun 15, 20228-KMaterial AgreementJun 2, 202210-Q10-QMay 4, 20228-KResults of OperationsMay 4, 2022DEFA14ADEFA14AApr 21, 2022DEFA14ADEFA14AApr 21, 2022DEF 14ADEF 14AApr 21, 20228-KMaterial Agreement · New Debt / ObligationMar 8, 2022SC 13GSCHEDULE 13GFeb 11, 202210-K10-KFeb 7, 20228-KResults of OperationsFeb 4, 20228-KResults of Operations · Reg FD DisclosureJan 10, 202210-Q10-QNov 4, 20218-KResults of OperationsNov 4, 20218-KMaterial AgreementSep 16, 202110-Q10-QAug 5, 2021
Insider Activity
In the 90 days to Mar 2, 2026: 4 sold $4.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $789.28 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 20 | $788.96 | $16K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 11 | $785.48 | $9K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 10 | $783.62 | $8K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 9 | $784.48 | $7K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $786.61 | $6K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 7 | $777.46 | $5K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 5 | $779.69 | $4K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 3 | $780.69 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $787.34 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $782.62 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $781.21 | $2K |
| Mar 2, 2026 | Ryan Arthur FDirector | Sell | 2 | $778.30 | $2K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 331 | $780.45 | $258K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 298 | $782.10 | $233K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 220 | $783.29 | $172K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 209 | $781.28 | $163K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 208 | $779.55 | $162K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 160 | $784.45 | $126K |
| Feb 19, 2026 | Zoghbi Huda YDirector | Sell | 56 | $785.61 | $44K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 5 reputable articles · skews – neutral.
MarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day12d agoMarketWatchRegeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market18d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors21d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains24d agoMarketWatchRegeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains25d agoMarketWatchRegeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance